Skip to main content
. 2020 Apr 20;117(18):9964–9972. doi: 10.1073/pnas.1913633117

Fig. 7.

Fig. 7.

Triptolide suppresses IDH1-mutated xenograft expansion in vivo. (A) Schematic illustration for the xenograft modeling and triptolide treatment. (B) The tumor growth curve shows that triptolide suppresses tumor growth by measuring tumor volume. n = 8. **P < 0.01. (C) Tumor imaging shows that triptolide treatment suppressed IDH1-mutated xenograft in vivo. (D) Quantification of tumor weight shown in C. n = 8. **P < 0.01. (E) Immunohistochemistry staining of the expression of Nrf2, SLC7A11m GCLC, and GCLM in TS603 xenograft tissues after mice received triptolide treatment. (F) immunohistochemistry staining of H&E, Ki67, γH2A.X, and TUNEL assay in TS603 xenograft tissues after mice received triptolide. Bar = 50 μm. (G) Quantification of integrated optical density of immunohistochemistry staining in E and F. n = 6. ***P < 0.001, **P < 0.01, *P < 0.05. (H) Kaplan-Meier analysis of intracranial xenografts in mice that received triptolide treatment.